Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
Varettoni
Marzia
M
Vassallo
Camilla
C
Borroni
Giovanni
G
Mangiacavalli
Silvia
S
Zappasodi
Patrizia
P
Rosso
Renato
R
Lazzarino
Mario
M
Corso
Alessandro
A
D000212:Acyclovir / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use; D005076:Exanthema / Q000139:chemically induced* / Q000188:drug therapy; D006562:Herpes Zoster / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D012867:Skin / Q000187:drug effects / Q000473:pathology / Q000821:virology; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D000998:Antiviral Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D000212:Acyclovir